The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats

Histology and Histopathology

Volumn 23, Issue 5, 2008, Pages 581-591

  Díaz Gil, Juan J ^a   García Monzón, Carmelo ^b   Rúa, Carmen ^c   Martín Sanz, Paloma ^d   Cereceda, Rosa M ^a   Miquilena Colina, María E ^b   Machín, Celia ^c   Fernández Martínez, Amalia ^d   García Cañero, Rafael ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Bile duct ligated rats; Cirrhosis; Fibrosis; Regeneration

Indexed keywords

RATTUS;

ALBUMIN BILIRUBIN COMPLEX; ALBUMIN-BILIRUBIN COMPLEX; BILIRUBIN; GELATINASE A; GELATINASE B; GROWTH PROMOTOR; SERUM ALBUMIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BREATH ANALYSIS; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; HEPATIC DUCT; LIGATION; LIVER; LIVER FUNCTION TEST; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY; RAT; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; BILE DUCTS, EXTRAHEPATIC; BILIRUBIN; BLOTTING, WESTERN; BREATH TESTS; DISEASE MODELS, ANIMAL; GROWTH SUBSTANCES; LIGATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TESTS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; ORGAN SIZE; RATS; RATS, WISTAR; SERUM ALBUMIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864305413     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aronson D.C., Chamuleau R.A.F.M., Fredericks W.M., Gooszen H.G., Hiijmans H.S. and James J. (1993). Reversibility of cholestatic changes following experimental common bile duct obstruction: fact or fantasy? J. Hepatol. 18, 85-95
2. Arthur M.J.P. (2000). Fibrogenesis. II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G245-49.
3. Barbara N.P., Wrana J.L. and Letarte M. (1999). Endoglin is an accesory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-ß superfamily. J. Biol. Chem. 274, 584-594.
4. Bataller R. and Brenner D.A. (2005). Liver fibrosis. J. Clin. Invest.115, 209-218.
5. Biecker E., De Gottardi A., Neef M., Unternahrer M., Scheider V., Ledermann M., Sagesser H., Show S. and Reichen J. (2005). Long-term treatment of bile duct ligated rats with (sirolimus) rapamycin significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther. 313, 952-961.
6. Bissell D.M., Roulot D. and George J. (2001). Transforming growth factor ß and the liver. Hepatology 34, 859-67.
7. Clemente M., Núñez O., Lorente R., Rincón D., Matilla A., Salcedo M., Catalina M.V., Ripio C., Iacono O.L., Banares R., Clemente G. and García-Monzón C. (2006). Increased intrahepatic and circulating levels of endoglin, a TGF-beta1co-receptor, in patients with chronic hepatitis C virus infection: Relationship to histological and serum markers of hepatic fibrosis. J. Viral Hepatol. 13, 625-632.
8. D́Amico G., Garcia-Tsao G. and Pagliaro L. (2006). Natural history and
9. prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217-231
10. De Bleser P.J., Niki T., Rogiers V. and Geerts A. (1997). Transforming growth factor-ß gene expression in normal and fibrotic rat liver. J. Hepatol. 26, 886-893.
11. Díaz-Gil J.J., Escartín P., García-Cañero R., Trilla C., Veloso J.J., Sánchez G., Moreno-Caparrós A., Enrique de Salamanca C., Lozano R., Gavilanes J.C. and García-Segura J.M. (1986). Purification of a liver DNA-synthesis promoter from plasma of partially hepatectomized rats. Biochem. J. 235, 49-55.
12. Díaz-Gil J.J., Gavilanes J.G., Sánchez G., García-Cañero R., García-Segura J.M., Santamaría L., Trilla C. and Escartín P. (1987). Identification of a liver growth factor as an albumin-bilirubin complex. Biochem. J. 243, 443-448.
13. Díaz-Gil J.J., Sánchez G., Trilla C., Escartín P. (1988). Identification of biliprotein as a liver growth factor. Hepatology 8, 484-486.
14. Díaz-Gil J.J., Rúa C., Machín C., Cereceda R.M., de Foronda M., Pérez de Diego J., Trilla C. and Escartín P. (1994a). Hepatic growth induced by injection of the liver growth factor into normal rats. Growth Regul. 4, 113-22.
15. Díaz-Gil J.J., Rúa C., Machín C., cereceda R.M., Guijarro M.C. and Escartín P. (1994b). Hepatic recovery of dimethylnitrosamine-cirrhotic rats after injection of the liver growth factor. In: Liver carcinogenesis. The molecular pathways. Skouteris G.G. (ed). NATO ASI Series. Vol. 88. Springer-Verlag. Berlin. pp 275-288.
16. Díaz-Gil J.J., Muñoz J., Albillos A., Rúa C., Machín C., García-Cañero R., Cereceda R.M., Guijarro M.C., Trilla C. and Escartín P. (1999). Improvement of liver fibrosis, functionality and hemodynamics in CCl4-cirrhotic rats alter injection of the liver growth factor. J. Hepatol. 30, 1065-1072.
17. Díaz-Gil J.J., Majano P.L., López-Cabrera M., Sánchez-López V., Rúa C., Machín C., Trilla C., García-Cañero R. and Moreno-Otero R. (2003). The mitogenic activity of the liver growth factor is mediated by tumor necrosis factor alpha in rat liver. J. Hepatol. 38, 598-604.
18. Franco D., Gigou M., Szeley A.-M. and Bismuth H. (1979). Portal hypertension after bile duct obstruction. Effect of bile diversion on portal pressure in the rat. Arch. Surg. 114, 1064-1067.
19. García L., Hernández I., Sandoval A., Salazar A., García J., Vera J., Grijalva G., Muriel P., Margolin S. and Armendáriz-Borunda J. (2002). Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 37, 797-805.
20. Gluud C. (2005). Mortality from cirrhosis: lack of progress over the last 35 years. Gut 54, 1523-1526.
21. Gressner A.M., Weiskirchen R., Breitkopf H. and Dooley S. (2002). Roles of TGF-ß in hepatic fibrosis. Front. Biosci. 7, D793-807.
22. Gressner A.M. and Weiskirchen R. (2006). Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-ß as major players and therapeutic targets. J. Cell. Mol. Med. 10, 76-99.
23. Greupink R., Bakker H.I., Bouma W., Reker-Smit C., Meijer D.K., Beljaers L. and Poelstra K. (2006). The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J. Pharmacol. Exp. Ther. 317, 514-521.
24. Kossakowska A.E., Edwards D.R., Lee S.S., Urbanski L.S., Stabber A.L., Zhang C.L., Phillips B.W., Zhang Y. and Urbanski S.J. (1998). Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am. J. Pathol. 153, 1895-1902.
25. Kountouras J., Billing B.H. and Scheuer P.J. (1984). Prolonged bile duct ligation obstruction: a new experimental model of cirrhosis in the rat. Br. J. Exp. Pathol. 65, 305-311.
26. Lauterburg B.H. and Bircher J. (1976). Expiratory measurement of maximal aminopyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, portacaval shunt and bile duct ligation in the rat. J. Pharmacol. Exp. Ther. 196, 501-509.
27. Letamendia A., Lastres P., Botella L.M., Roab U., Longa C., Velasco B., Attisane L. and Bernabeu C. (1998). Role of endoglin in cellular responses to transforming growth factor b. A comparative study with betaglycan. J. Biol. Chem. 273, 33011-33019.
28. Liu X., Hu H. and Yin J.Q. (2006). Therapeutic strategies against TGF-ß signaling pathway in hepatic fibrosis. Liver Int., 26, 8-22.
29. Mas M.R., Comert B., Oncu K., Vural S.A., Akay C. and Tasci I. (2004). The effect of taurine treatment on oxidative stress in experimental liver fibrosis. Hepatol. Res. 28, 207-215.
30. Muriel P. (1996). Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in the rat. J. Hepatol. 24, 614-621.
31. Nakamura T., Sakata R., Ueno T., Sata M. and Ueno H. (2000). Inhibition of transforming growth factor ß prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32, 247-255.
32. Olaso E. and Friedman S.L. (1998). Molecular mechanisms of hepatic fibrogenesis. J. Hepatol. 29, 836-847.
33. Reimers D., Herranz A.S., Díaz-Gil J.J., Asensio M.V.T., Paíno C.L., and Bazán E. (2006). Intrastriatal infusión of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. J. Histochem. Cytochem. 54, 457-465.
34. Roeb E., Purucker E., Breuer B., Nguyen H., Heinrich P.C., Rose-John S. And Matern S. (1997). TIMP expression in toxic and cholestatic liver injury in rat. J. Hepatol. 27, 535-544.
35. Somoza B., Abderrahim F., González J.M., Conde M.V., Arribas S.M., Starcher B., Fernández-Alfonso M.S., Díaz-Gil J.J. and González M.C. (2006). Short term treatment of spontaneously hypertensive rats with liver growth factor reduces carotid artery fibrosis, improves vascular function, and lowers blood pressure. Cardiov. Res. 69, 764-71.
36. Vyas S.K., Leyland H., Gentry J. and Arthur M.J. (1995). Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 109, 889-898.
37. Wensing G. and Branch R. (1990). Phenobarbital influences the development of sodium retention in liver disease induced by bile duct ligation in the rat. Hepatology 11, 773-778.
38. Woessner J.F. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J. 5, 2145-2154.
39. Xia J.-L., Dai C., Michalopoulos G.K. and Liu Y. (2006). Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168, 1500-1512.
40. Zimmermann H., Reichen J., Zimmermann A., Sagesser H., Thenisch B. and Hoflin F. (1992). Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 103, 579-589.